Anika Therapeutics (ANIK) Cash from Operations (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cash from Operations data on file, last reported at 4846000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 4846000.0, down 3627.69% year-over-year; the trailing twelve-month figure through Mar 2026 was 6472000.0 (up 19.87% YoY), and the FY2025 annual result was 11188000.0, up 107.07% from the prior year.
• Cash from Operations slipped to 4846000.0 in Q1 2026 per ANIK's latest filing, from 4637000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 6870000.0 in Q3 2025 and troughed at 8293000.0 in Q2 2023.
• A 5-year average of 845058.82 and a median of 481000.0 in 2022 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2023 and 2026: Cash from Operations soared 656.34% in 2023, then plunged 3627.69% in 2026.
• A 5-year view of Cash from Operations shows it stood at 481000.0 in 2022, then soared by 656.34% to 3638000.0 in 2023, then tumbled by 56.51% to 1582000.0 in 2024, then soared by 193.11% to 4637000.0 in 2025, then tumbled by 204.51% to 4846000.0 in 2026.
• Business Quant data shows ANIK's Cash from Operations at 4846000.0 in Q1 2026, 4637000.0 in Q4 2025, and 6870000.0 in Q3 2025.